Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician’s choice of chemotherapy in patients with HER2-low mBC
The Oncologist · 08.05.2025 · 30 (5)
DOI: 10.1093/oncolo/oyaf048 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Oncologist, online erschienen am 11.05.2025. Verfasst von Naoto T Ueno und 19 weiteren Autor:innen. Beteiligte Einrichtung: Translational and Clinical Research Program, University of Hawai'i Cancer Center, Honolulu, HI, 96813, United States. Hauptthemen laut MEDLINE: Breast Neoplasms, Trastuzumab, Erb-b2 Receptor Tyrosine Kinases, Camptothecin. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Daiichi Sankyo, Inc, AstraZeneca..
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
The phase 3 DESTINY-Breast04 trial demonstrated superior efficacy and acceptable safety with trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy in previously treated patients with human epidermal growth factor receptor 2 (HER2)–low metastatic breast cancer (mBC). We report the patient-reported outcomes (PROs), focusing on the hormone receptor–positive cohort. Patients and Methods Patients were randomized 2:1 to T-DXd (5.4 mg/kg intravenously every 3 weeks) or physician’s choice of chemotherapy and prospectively assessed for PRO measures. Change from baseline and time to definitive deterioration (TDD) were calculated from the EORTC QLQ-C30 and QLQ-BR45 and the EQ-5D-5L questionnaires.
Results
Baseline global health status/quality of life (GHS/QoL) scores were similar between groups (T-DXd, 331 patients; physician’s choice, 163 patients); there were no clinically meaningful changes while on either treatment (median duration: T-DXd, 8.2 months; physician’s choice, 3.5 months). Median TDD for GHS/QoL was delayed with T-DXd vs physician’s choice (11.4 vs 7.5 months, respectively; hazard ratio, 0.69; 95% CI, 0.52-0.92). Median TDD for all prespecified PROs, including pain, favored T-DXd. In an additional analysis, the median TDD was shorter for nausea and vomiting with T-DXd vs the physician’s choice.
Conclusions
Trastuzumab deruxtecan maintained GHS/QoL scores despite a longer treatment course compared with standard chemotherapy and delayed definitive deterioration across all prespecified PROs vs the physician’s choice. Appropriate management of adverse events and use of preventive measures (ie, antiemetic prophylaxis) may further support patient health-related quality of life. These findings reinforce the benefit of T-DXd as an option for patients with HER2-low mBC. ClinicalTrials.gov: NCT03734029
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational and Clinical Research Program, University of Hawai'i Cancer Center, Honolulu, HI, 96813, United States.
- Global Oncology HEOR and RWE, Daiichi Sankyo, Rome, 00142, Italy.
- Global Oncology HEOR and RWE, Daiichi Sankyo, Uxbridge, UB8 1DH, United Kingdom.
- Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier University, INSERM U1194, Montpellier, 34298, France.
- Department of Breast Surgery and Oncology, Kanagawa Cancer Center, Yokohama, 241-8515, Japan.
- Department of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
ORCID-Profile: Naoto T Ueno, William Jacot, Toshinari Yamashita, Joohyuk Sohn, Aleix Prat, Junji Tsurutani, Fatima Cardoso, Nadia Harbeck
Förderung
- NCI NIH HHS
- Daiichi Sankyo, Inc
- AstraZeneca.
Zitieren
APA
Ueno, N. T., Cottone, F., Dunton, K., Jacot, W., Yamashita, T., Sohn, J., Tokunaga, E., Prat, A., Tsurutani, J., Park, Y. H., Rugo, H. S., Xu, B., Cardoso, F., Mitri, Z., Mahtani, R., Aguilar, C. O., Xiao, F., Harbeck, N., Cameron, D. A., & Modi, S. (2025). Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician’s choice of chemotherapy in patients with HER2-low mBC. The Oncologist, 30(5). https://doi.org/10.1093/oncolo/oyaf048
Vancouver
Ueno NT, Cottone F, Dunton K, Jacot W, Yamashita T, Sohn J, et al. Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician’s choice of chemotherapy in patients with HER2-low mBC. The Oncologist. 2025;30(5). doi:10.1093/oncolo/oyaf048
BibTeX
@article{Ueno2025,
author = {Ueno, Naoto T and Cottone, Francesco and Dunton, Kyle and Jacot, William and Yamashita, Toshinari and Sohn, Joohyuk and Tokunaga, Eriko and Prat, Aleix and Tsurutani, Junji and Park, Yeon Hee and Rugo, Hope S and Xu, Binghe and Cardoso, Fatima and Mitri, Zahi and Mahtani, Reshma and Aguilar, Cecilia Orbegoso and Xiao, Feng and Harbeck, Nadia and Cameron, David A and Modi, Shanu},
title = {Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician’s choice of chemotherapy in patients with HER2-low mBC},
journal = {The Oncologist},
year = {2025},
volume = {30},
number = {5},
doi = {10.1093/oncolo/oyaf048}
}
EUVIMED